Skip to main
GILD
GILD logo

Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences (GILD) Analyst Ratings

Based on 38 analyst ratings
Buy
Strong Buy 24%
Buy 37%
Hold 37%
Sell 0%
Strong Sell 3%

Bulls say

Gilead Sciences reported a robust financial performance, with fiscal year 2024 sales in its liver disease franchise reaching $3 billion, reflecting a year-over-year increase of 9%, driven by the successful launch of Livdelzi in primary biliary cholangitis. The company also experienced significant growth in its HIV segment, achieving sales of $19.6 billion for FY24, up 16% year-over-year, bolstered by higher demand and favorable market conditions, with Descovy's sales increasing 21% year-over-year to $616 million, surpassing expectations. Additionally, Gilead's commercial portfolio showed overall growth across multiple therapeutic areas, including a 12% year-over-year increase in oncology, further solidifying its positive outlook on future performance.

Bears say

Gilead Sciences faces a negative outlook primarily due to a projected decline in revenue from key products, including Veklury, which is expected to experience a continuous downward trend tied to decreasing COVID-19 hospitalizations, alongside anticipated declines in HIV revenue. The company's guidance suggests flat year-over-year revenue for FY25, with mid-teen percentage decreases quarterly, raising concerns about its ability to sustain growth amid increasing competition in both the hepatitis and oncology markets. Additionally, potential challenges in market penetration for CAR-T therapies and the execution of next-generation HIV treatments further compound the uncertainty surrounding Gilead's future financial performance.

Gilead Sciences (GILD) has been analyzed by 38 analysts, with a consensus rating of Buy. 24% of analysts recommend a Strong Buy, 37% recommend Buy, 37% suggest Holding, 0% advise Selling, and 3% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gilead Sciences (GILD) Forecast

Analysts have given Gilead Sciences (GILD) a Buy based on their latest research and market trends.

According to 38 analysts, Gilead Sciences (GILD) has a Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $102.34, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $102.34, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gilead Sciences (GILD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.